Tirzepatide Clinics in Ohio

What is Tirzepatide?

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It uniquely targets both the GIP and GLP-1 receptors, producing greater weight loss and blood sugar control than GLP-1-only medications. Approved as Mounjaro for type 2 diabetes (2022) and Zepbound for weight management (2023), tirzepatide has shown weight loss of up to 22.5% in clinical trials — the highest of any GLP-1 class medication.

Brand Names

Tirzepatide is available as Mounjaro, Zepbound, manufactured by Eli Lilly.

Expected Weight Loss

In the SURMOUNT-1 trial, participants on tirzepatide 15 mg lost an average of 22.5% of their body weight over 72 weeks. At the 10 mg dose, average weight loss was 21.4%. Over a third (36%) on the highest dose lost 25% or more of their body weight, and 63% lost 20% or more.

Cost in Ohio

Without insurance, Tirzepatide typically costs $1,000-$1,200/month (Mounjaro), $1,000-$1,100/month (Zepbound). With insurance, costs range from $25-$200/month (varies by plan). Compounded options may be available at $250-$550/month.

Savings programs: Eli Lilly offers the Zepbound Savings Card (commercially insured patients may pay as low as $25/month) and the LillyDirect platform for direct-to-patient delivery.